{"filings":[{"id":1509156,"accession_number":"0001570562-26-000079","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2026-07-08T13:03:46+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Evolus licenses Profhilo for U.S. skin-quality market; no upfront payment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive license to develop and commercialize Profhilo in the U.S. for aesthetics and dermatology.","No upfront or milestone payments; economics via transfer-price model supporting target gross margins.","Evolus responsible for U.S. development and FDA approval; initial term 15 years from first approval.","Profhilo has 4.8M+ treatments globally since 2015; market leader in European injectable skin quality.","Agreement does not affect 2026 revenue/opex/operating profit outlook or 2028 targets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1027798,"accession_number":"0001570562-26-000076","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2026-06-12T20:19:03+00:00","items":["5.07"],"status":"ready","headline":"Evolus stockholders re-elect Brady Stewart and Vikram Malik as Class II directors; ratify auditor; approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Brady Stewart elected with 38,479,626 for (1,662,228 withhold); Vikram Malik with 21,310,653 for (18,831,201 withhold).","Ernst & Young LLP ratified as independent auditor for FY 2026 with 51,230,324 for, 63,992 against, 18,696 abstain.","Advisory vote on named executive officer compensation approved with 39,350,651 for, 336,958 against, 441,629 abstain.","All three proposals passed; broker non-votes of 11,183,774 on director election and say-on-pay.","Annual meeting held June 11, 2026; results are routine and no change in leadership or auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93744,"accession_number":"0001570562-26-000064","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Evolus Q1 2026 rev $73.1M (+7% YoY); Adjusted EBITDA positive $0.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Global net revenue $73.1M (+7% vs Q1 2025); GAAP operating loss narrowed to $6.8M from $15.2M.","Second consecutive quarter of positive Adj EBITDA ($0.6M) vs ($5.5M) loss in Q1 2025.","Reaffirmed FY2026 net revenue guidance $327M-$337M (10-13% growth) and low- to mid-single digit Adj EBITDA margin.","Cash $49.8M at quarter end; terminated $50M ATM with no shares sold; ~$120M additional capacity noted.","Potential 15% tariff on Jeuveau from Sep 29, 2026; company says it has flexibility to mitigate near-term impact."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":73137000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105617,"accession_number":"0001570562-26-000043","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Evolus reclassifies Vikram Malik to Class II director after board refresh","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Simone Blank stepped down from the Board to support refreshment efforts, causing class imbalance.","Vikram Malik resigned as Class III director and was immediately appointed as Class II director.","Board now has six directors, with two in each class (Class I, II, III).","Malik continues as Chairman and Compensation Committee member; no new equity award granted.","Reclassification effective March 13, 2026; Malik's service was continuous and uninterrupted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105616,"accession_number":"0001628280-26-013872","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["1.01","2.02","2.03","9.01"],"status":"ready","headline":"Evolus Q4 GAAP operating income $4.2M; FY25 revenue $297.2M up 12%; guides 2026 rev $327-337M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP operating income $4.2M vs loss $2.3M YoY; Non-GAAP operating income $7.1M, above guidance.","Full-year 2025 revenue $297.2M, up 12% YoY; sixth consecutive year of double-digit growth.","2026 revenue guidance $327M-$337M (10-13% growth); expects low- to mid-single-digit adjusted EBITDA margin.","Entered $30M secured revolving credit facility with Eclipse Business Capital (SOFR+4.25%, matures March 2029).","Evolysse (device from France) subject to 10% tariff; evaluating recovery; Jeuveau not impacted by tariffs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105615,"accession_number":"0001570562-26-000003","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolus Q4 2025 prelim rev $88.6-90.6M (+12-15%); 2026 rev guide $327-337M; targets profitability","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2025 net revenue $88.6M-$90.6M, 12-15% YoY growth; positive non-GAAP op income $5M-$7M.","FY 2025 net revenue $295.5M-$297.5M, 11-12% YoY; Evolysse HA gels contributed ~8% of total revenue.","2026 guidance: net revenue $327M-$337M (11-13% growth); sustainable annual profitability commencing in 2026.","Updated 2028 long-term outlook: net revenue $450M-$500M (15-19% CAGR); non-GAAP op margin 13-15%.","Cash $53M at Dec 31, 2025, up from $43.5M at Sep 30, 2025, reflecting strong sales and expense management."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":297176000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121900,"accession_number":"0001628280-25-049564","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolus Q3 revenue $69M (+13% YoY); expects Q4 non-GAAP operating profit $5-7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total net revenue $69.0M, up 13% YoY; global Jeuveau $63.2M, Evolysse $5.7M.","GAAP operating loss $11.5M; non-GAAP operating loss $3.1M, improved from $6.7M in Q3 2024.","Now expects positive non-GAAP operating income of $5M-$7M in Q4 2025 and sustainable annual profitability from 2026.","Reaffirms FY2025 revenue guidance $295M-$305M and non-GAAP OpEx $208M-$213M.","Evolysse launch with $5.7M revenue described as strongest HA filler debut in over a decade."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":206876000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138590,"accession_number":"0001570562-25-000110","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Evolus appoints Tatjana Mitchell as CFO effective Sept 8, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Tatjana Mitchell as CFO; previously SVP Finance at Experian, CFO of Experian Consumer Services.","Base salary $490K; signing bonus $100K (subject to clawback); target annual bonus 55% of base.","Received inducement equity: option and RSUs each valued at $750K; option vests over 4 years, RSUs over 3-4 years.","Severance: 12 months base + prorated bonus (non-cause); 18 months base + full target bonus + equity acceleration (change-in-control)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138589,"accession_number":"0001570562-25-000094","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Evolus Q2 revenue $69.4M (+4% YoY); cuts FY2025 guidance to $295-305M; CEO appointed PFO, CMO departing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net revenue $69.4M, up 4% YoY; GAAP op loss $10.2M vs $7.7M loss YoY; non-GAAP op loss $7.9M vs $1.1M income.","FY2025 revenue guidance reset to $295-305M (11-15% growth); non-GAAP op expenses $208-213M with $25M savings.","Evolysse filler delivered $9.7M revenue in Q2, strongest filler launch quarter in over a decade.","CEO David Moatazedi appointed as Principal Financial Officer; CMO Tomoko Yamagishi-Dressler departing Aug 22, no disagreement.","Expects meaningful profitability in Q4 2025 and annual profitability from 2026; 15% Evolysse tariff minimal impact."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":137909000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156042,"accession_number":"0001570562-25-000085","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Evolus annual meeting elects directors; Director Blank departs in planned transition","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Simone Blank stepped down from board effective June 5, 2025, as part of planned refreshment; no disagreement.","Stockholders elected David Gill (31.5M for) and Albert White III (36.8M for) as Class I directors until 2028.","Ratification of Ernst & Young as auditor for 2025: 48.35M for, 0.19M against, 7K abstain.","Advisory vote on named executive officer compensation passed: 35.68M for, 1.23M against, 11.44M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156041,"accession_number":"0001570562-25-000083","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Evolus CFO Sandra Beaver resigns effective June 13, 2025, to join private mental health tech company","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sandra Beaver resigns as CFO effective June 13, 2025; no disagreement with the company on operations or accounting.","Beaver leaves to become CFO at a private mental health and wellness technology company.","Company has initiated a search for successor; experienced finance team to lead interim.","CEO cites strong momentum: recent second product launch, record revenues, solid balance sheet, path to profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156040,"accession_number":"0001570562-25-000074","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolus Q1 revenue $68.5M (+15.5% YoY); reaffirms FY2025 guidance; Evolysse launch strong","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 global net revenue $68.5M, up 15.5% from Q1 2024 on higher volumes and market share gains.","GAAP operating loss $15.2M; non-GAAP operating loss $5.5M (excludes stock-based comp, depreciation).","Reaffirmed FY2025 revenue guidance $345M to $355M, representing 30-33% growth over 2024.","Evolysse HA filler launched April 2025; strong early adoption; expected 8-10% of 2025 revenue.","On track for positive non-GAAP operating income in Q4 2025 and full-year 2025; tariffs no impact."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":68522000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156039,"accession_number":"0001570562-25-000069","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Evolus refinances with $250M credit facility, cuts interest cost by 350 bps","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $250M senior secured term loan replaces existing $125M facility; $150M drawn at closing, $100M incremental capacity available in two $50M tranches through Dec 31, 2026.","Interest rate reduced by 350 bps to SOFR + 5.00% (floor 3.50%); quarterly interest payments, bullet maturity at 5 years.","Converted from amortizing to bullet maturity; significantly reduced prepayment fees; no additional performance conditions or financial covenants for incremental tranches.","Evolus no longer required to make principal payments in 2026; refinancing enhances cash generation and financial flexibility.","Funds managed by Pharmakon Advisors, LP; Leerink Partners served as exclusive financial advisor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174504,"accession_number":"0001570562-25-000017","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolus reports record Q4 2024 revenue $79.0M (+30% YoY); achieves full-year profitability ahead of expectations","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q4 revenue $79.0M (+30% YoY); full-year $266.3M (+32% YoY).","GAAP op loss improved to $2.3M Q4; non-GAAP op income $6.7M Q4 and $0.3M full year (profitability ahead of schedule).","Evolysse FDA approval Feb 2025; launch Q2 2025; expected 8-10% of 2025 revenue.","2025 revenue guidance $345-355M (30-33% growth); expects positive non-GAAP op income for full year.","Added ~2,900 new accounts in 2024; total >15,300 accounts; over 50% US account penetration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174503,"accession_number":"0001570562-25-000006","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolus posts record FY2024 revenue $266.3M (+32%); guides 2025 $345-355M; FDA for HA gels within 90 days","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2024 net revenue $79.0M (+30% YoY); FY2024 net revenue $266.3M (+32% YoY) at top of guidance ($260-266M).","Expects FDA approval within 90 days for Evolysse Form and Smooth HA gels; US launch planned Q2 2025, a quarter ahead of prior timeline.","2025 revenue guidance $345-355M (30-33% growth); non-GAAP operating expenses $230-240M; positive non-GAAP operating income expected for full-year 2025.","Cash and equivalents $87M as of Dec 31, 2024, up from $85M on Sep 30; >15,300 accounts purchasing Jeuveau since launch.","Evolus Rewards enrollment grew over 40% to ~1.1M; Q4 redemptions record ~220,000, with ~60% from repeat treatments."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":266274000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191454,"accession_number":"0001570562-24-000127","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolus Q3 revenue $61.1M (+22% YoY); narrows FY2024 guidance to $260-266M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net revenue $61.1M, up 22% from $50.0M in Q3 2023; year-to-date growth 33%.","Full-year 2024 revenue guidance narrowed to $260-266M (29-32% YoY growth).","Received EU approval for Estyme HA gels; U.S. PMA for Evolysse under FDA review, launch expected by Sep 2025.","Evolus Rewards loyalty program exceeded 1M enrolled consumers and 2M total redemptions.","Reaffirms positive non-GAAP operating income target for Q4 2024 and full year 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":187327000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207932,"accession_number":"0001570562-24-000114","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolus Q2 revenue $66.9M (+36% YoY); raises FY2024 guidance to $260-270M; first positive non-GAAP operating income","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net revenue of $66.9M for Q2 2024, up 36% YoY from $49.3M.","GAAP operating loss improved to $7.7M; first positive non-GAAP operating income of $1.1M.","Raised full-year 2024 net revenue guidance to $260M-$270M (top end 34% YoY growth).","PMA submitted to FDA for Evolysse Lift and Smooth fillers; approval and launch expected H2 2025.","Added 770 new customer accounts; total ~14,000 since launch; reorder rate ~70%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":126242000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207931,"accession_number":"0001570562-24-000104","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Evolus appoints CooperCos CEO Albert White to board; Hayman steps down","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Albert White III, CEO of CooperCompanies (COO), elected to Evolus board effective July 1, 2024.","White to serve as Class I director and on Compensation Committee; receives ~$255K in RSUs vesting over 2 years.","Robert Hayman voluntarily stepped down as planned; David Gill becomes Compensation Committee chair.","Board now seven directors, six independent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225443,"accession_number":"0001570562-24-000098","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Evolus stockholders approve 2024 ESPP and elect three Class III directors at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved 2024 ESPP effective June 6, 2024, authorizing up to 579,648 shares with annual increases.","David Moatazedi, Vikram Malik, and Karah Parschauer elected as Class III directors for three-year terms; Malik and Parschauer received significant withhold votes (7.6M and 8.5M, respectively).","Ernst & Young ratified as independent auditor for FY 2024; advisory vote on executive compensation approved with ~91% support; frequency vote set at one year.","ESPP allows eligible employees to purchase shares at up to 85% of FMV (lesser of grant/exercise date), with max 15% compensation contribution and 5,000 share limit per offering period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225442,"accession_number":"0001570562-24-000078","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolus Q1 revenue up 42% YoY to $59.3M; on track for non-GAAP profitability in Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $59.3M (+42% YoY); gross margin 68.3%; non-GAAP loss from ops $0.9M, narrowing from Q4 2023's $3.7M.","Reaffirms FY2024 revenue guidance of $255-265M; expects non-GAAP profitability in Q4 2024 and full-year 2025.","FDA submission for Evolysse dermal fillers within 90 days; expanding into Australia and Spain with Nuceiva.","Added 700+ new customer accounts; reorder rate ~70%; Evolus Rewards members ~825,000."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":59333000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225441,"accession_number":"0001570562-24-000061","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2024-04-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Evolus directors Hayman and Blank plan to step down as part of board refreshment","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Hayman to step down upon identification and appointment of a replacement director.","Simone Blank to step down by 2025 Annual Meeting or upon replacement appointment, whichever occurs first.","Both departures are planned transitions with no disagreement regarding operations, policies, or practices.","Company is searching for suitable replacements to fill the upcoming vacancies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244622,"accession_number":"0001570562-24-000049","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Evolus prices public offering of 3.55M shares at $14.07/share; net proceeds ~$46.9M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriters Leerink and Stifel purchase 3,554,000 shares at $13.2258/share; option for 533,100 more.","Estimated net proceeds of $46.9M (up to $54.1M if option exercised) to fund Jeuveau growth, Evolysse launch.","Lock-up agreements restrict insider sales for 60 days from March 11, 2024.","Offering closed on March 13, 2024; proceeds also for potential business development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244621,"accession_number":"0001570562-24-000038","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolus reports record Q4 revenue $61.0M (+40% YoY); guides to Q4 2024 profitability","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2023 net revenue $202.1M (+36% YoY); Q4 record $61.0M (+40% YoY).","Q4 non-GAAP operating loss narrowed to $3.7M from $5.7M in Q3; full-year non-GAAP loss down 48% to $23.4M.","Reaffirms 2024 revenue guidance $255-265M (26-31% growth); expects positive non-GAAP operating income in Q4 2024 and full year 2025.","Added 840+ new Jeuveau accounts in Q4, total >12,400; loyalty program grew 55% to 750,000 members.","Plans to file PMA for first two Evolysse fillers by mid-2024; targets at least $700M net revenue by 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244620,"accession_number":"0001570562-24-000003","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2024-01-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolus reports preliminary FY2023 net revenue $202M, above guidance; guides FY2024 $255-265M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2023 net revenue ~$61M, up 40% YoY and 22% sequential; FY2023 net revenue ~$202M, +36% YoY.","FY2023 net revenue exceeded top end of guidance ($194-198M); 2024 guidance $255-265M (26-31% growth).","Cash and equivalents $62.8M at Dec 31, 2023, up from $38.7M at Sept 30; expects existing liquidity to fund to profitability in 2025.","Non-GAAP operating expense guidance for 2024: $185-190M; expects non-GAAP operating income positive in 2025.","Accounts purchasing Jeuveau increased by record 840+ in Q4; total accounts >12,400 since launch; reorder rate ~70%."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":202085000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262054,"accession_number":"0001570562-23-000119","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2023-12-20T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Evolus signs exclusive deal with Symatese for four dermal fillers in Europe; issues 610,000 shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive rights to distribute Lift, Smooth, Sculpt, and Lips fillers under Estyme® brand in 50 European countries.","Consideration includes 610,000 common shares to Symatese and up to €3.1M in milestone payments.","European regulatory approvals expected H2 2024; commercialization targeted for 2025.","No material impact on 2025 profitability target; company to pre-announce Q4/FY 2023 results and 2024 guidance in January.","Evolus licenses Nuceiva® to Symatese for France; sub-licenses Estyme® distribution in France to Symatese subsidiary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262053,"accession_number":"0001570562-23-000114","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolus reports record Q3 revenue $50M (+48% YoY); raises FY guidance; 40U shows 26-week duration","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue of $50.0M, up 48% from $33.9M in Q3 2022; operating cash burn only $0.9M.","Raised FY2023 revenue guidance from $185-195M to $194-198M, representing over 30% YoY growth.","Phase II data for extra-strength 40U Jeuveau shows 26-week (6-month) duration; presented at ASDS.","Added 650+ new customer accounts; total ~11,600; reorder rate >70%; loyalty members 671,000.","Expects non-GAAP operating income in 2025; projects revenue can reach $700M by 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":141086000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279260,"accession_number":"0001570562-23-000086","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolus Q2 revenue $49.3M (+33% YoY); raises FY2023 guidance to $185-195M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $49.3M, up 33% YoY; loss from ops $15.1M including $4.4M milestone payment.","Raises full-year 2023 net revenue guidance to $185-195M, representing >30% YoY growth at upper end.","Cash $41.7M at June 30; net cash used in ops $13.3M; expects sustained profitability in 2025.","Added ~800 new customer accounts in Q2; total treatments >147,000; loyalty program 638,000 members."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":91067000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279259,"accession_number":"0001570562-23-000082","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2023-07-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolus raises FY2023 revenue guidance to $185-195M, Q2 revenue $49.3M (+33% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net revenue $49.3M, up 33% YoY, a new quarterly record.","FY2023 revenue guidance raised to $185-195M from prior $180-190M.","Record ~800 new accounts, 64k new patient enrollments, 147k+ redemptions.","Expanding into fillers in 2025; targeting $700M revenue by 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":91067000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297616,"accession_number":"0001570562-23-000079","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2023-06-14T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Evolus shareholders approve doubling authorized shares to 200M, elect Blank and Stewart as directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved increase in authorized common shares from 100M to 200M (45.5M for, 0.97M against).","Simone Blank elected as Class II director (33.99M for, 2.41M withhold) for term ending 2026.","Brady Stewart elected as Class II director (34.03M for, 2.36M withhold) for term ending 2026.","Ratification of Ernst & Young as independent auditor for FY2023 (46.28M for, 0.21M against).","Certificate of Amendment filed with Delaware Secretary of State on June 12, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297615,"accession_number":"0001570562-23-000068","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["1.01","2.02","2.03","7.01","8.01","9.01"],"status":"ready","headline":"Evolus Q1 revenue up 23% to $41.7M; enters filler market; raises 2028 outlook to $700M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net revenue $41.7M, +23% YoY; reaffirms FY2023 guidance of $180-190M.","Signs exclusive U.S. distribution deal with Symatese for 5 dermal fillers (Evolysse); first approval expected 1H2025.","Raises 2028 revenue outlook to $700M (from $500M), implying ~29% CAGR from combined Jeuveau and filler line.","Amends Pharmakon debt to draw $50M second tranche in two installments ($25M May 2023, $25M Dec 2023); extends interest-only period 12 months.","CEO David Moatazedi awarded 560,000 performance RSUs; vests if stock price ≥$30 (40%) or ≥$50 (60%) within 5 years."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":41721000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317903,"accession_number":"0001570562-23-000042","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Evolus discloses no deposits at SVB or Signature Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Evolus holds no deposits at Silicon Valley Bank or Signature Bank.","Company has no other direct investments at SVB or Signature.","Disclosure made on March 13, 2023 amid banking sector turmoil."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317902,"accession_number":"0001570562-23-000034","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolus Q4 revenue $43.6M (+26% YoY); FY22 revenue $148.6M (+49%); reaffirms FY23 guidance $180-190M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net revenue $43.6M, up 26% YoY; FY22 net revenue $148.6M, up 49% YoY (top end of guidance).","Reaffirms FY2023 net revenue guidance of $180-190M, expecting positive non-GAAP operating income in Q4 2023.","Adjusted gross margin FY22 62.4%, above guidance; expects FY23 adjusted gross margin 68-71%.","Added 2,500+ new customer accounts in 2022, total >9,500; Evolus Rewards membership >500K, up 75% YoY.","Interim Phase II data showed extra-strength Jeuveau lasting 26 weeks vs ~21 weeks for controls; international expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317901,"accession_number":"0001570562-23-000003","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2023-01-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolus Q4 2022 net rev $43.6M (+26% YoY); projects Q4 2023 profitability, $500M revenue aspiration by 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 prelim net revenue ~$43.6M (+26% YoY); FY2022 ~$148.6M (+49% YoY), at top end of $143-150M guidance.","2023 net revenue guidance $180-190M; projects positive non-GAAP operating income in Q4 2023.","Long-term aspiration: organic net revenue of $500M by 2028, representing 22% CAGR.","Accounts purchasing Jeuveau >9,500 since launch; Evolus Rewards membership ~505,000 (+85% YoY).","Cash and equivalents ~$53.9M at year-end; $50M credit facility tranche undrawn through Dec 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":148616000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336170,"accession_number":"0001570562-22-000149","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2022-12-13T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Evolus amends Daewoong supply pact: exits Russia, revamps Europe pricing","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Evolus exits Russia; all rights to neurotoxin distribution revert to Daewoong.","European pricing changed from fixed transfer price to net-sales-based price with quarterly true-up.","Transfer price renegotiated annually; floor price per vial set.","Evolus must meet launch schedule and reporting obligations; failure allows Daewoong to revert pricing.","Parties to cooperate on transferring Russia regulatory materials to Daewoong."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336169,"accession_number":"0001570562-22-000146","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2022-12-08T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Evolus extends $50M undrawn tranche availability to Dec 2023","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Second $50M tranche under $125M term loan facility now available until Dec 31, 2023 (extended from Dec 31, 2022).","Paid $500K amendment fee; all other terms unchanged (3-month LIBOR +8.5%, interest-only first 36 months).","First $75M tranche fully drawn in 2021; company expects existing cash to fund operations through breakeven.","CEO cites market share gains and millennial demographic focus; Pharmakon continues to support the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336168,"accession_number":"0001570562-22-000141","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolus Q3 revenue +27% to $33.9M; reiterates FY2022 guidance at top end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $33.9M (+27% YoY); deferred $3.5M incremental due to 'Switch Your Tox' campaign, understating growth.","FY2022 revenue guidance top end $143-150M; non-GAAP opex guidance lowered to lower half of $135-140M.","Cash $65.6M; expects to fund through breakeven; operating cash use $17.1M, $3.8M less than Q2.","Added 650 new accounts (total >8,800); Evolus Rewards ~450,000 members with record 100,000 redemptions.","Launched Great Britain ops for Nuceiva; Phase II extra-strength Jeuveau enrollment completed."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":104970000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353597,"accession_number":"0001570562-22-000121","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2022-08-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Evolus appoints Sandra Beaver as CFO effective September 5, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sandra Beaver appointed CFO; most recently SVP of Finance at Experian, 17 years at IGT.","Base salary $420,000; signing bonus $100,000 (repayable if leaves within 1-2 years).","Target annual bonus 40% of base salary; equity inducement grants: option valued at $1.125M, RSUs $375,000.","Option and RSUs vest over 4 years; granted as inducement per Nasdaq Listing Rule 5635(c)(4), not under 2017 Omnibus Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353596,"accession_number":"0001570562-22-000116","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2022-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolus Q2 revenue $37.2M (+42% YoY); reaffirms FY upper-end guidance $143-150M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net revenue $37.2M, up 42% YoY; gross margin 55.4% (adj. 57.4%); operating loss $21.3M.","Reaffirms FY2022 revenue guidance upper end of $143-150M, expects ~50% YoY growth.","Cash $84.5M; expects funding to cash-flow breakeven; Q4 gross margin step-up to 68-71% after royalty end.","European Nuceiva launch on track for Q3 2022; Phase II 'extra strength' Jeuveau enrollment completed.","Added 590 new customer accounts in Q2; total >8,100 purchasing customers; reorder rate >70%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":71071000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371332,"accession_number":"0001570562-22-000110","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Evolus stockholders elect three Class I directors, ratify EY as auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["David Gill, Robert Hayman, and Peter Farrell elected as Class I directors for three-year terms ending 2025.","Gill received 30,117,783 'for' votes; Hayman 30,115,901; Farrell 28,373,668; each had ~7.7M broker non-votes.","Ratification of Ernst & Young as independent auditor for FY 2022: 42,167,313 for, 60,426 against, 10,522 abstain.","Annual meeting held June 8, 2022; all proposals passed based on disclosed vote counts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371331,"accession_number":"0001570562-22-000100","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolus Q1 revenue jumps 177% to $33.9M; guides to upper end of FY2022 range $143-150M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $33.9M vs $12.2M in Q1 2021, driven by higher volumes and slightly higher ASP.","Added 575 new customer accounts in Q1, total base >7,500; reorder rate above 70%.","Non-GAAP loss from operations narrowed 19% to $10.3M from $12.6M YoY.","Cash $106.7M; company expects to fund operations to breakeven without additional capital.","Full-year adjusted gross margin guidance 58%-61%; Q4 step-up to 68%-71% as royalty rates drop."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":33908000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390317,"accession_number":"0001570562-22-000071","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2022-03-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Evolus CFO Lauren Silvernail to retire effective May 31, 2022; successor search underway","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Lauren Silvernail to retire on May 31, 2022, for personal reasons; no disagreements with company.","Separation agreement includes 9 months base salary, pro-rated 2022 bonus, COBRA through Sep 2023, and accelerated equity vesting.","Successor search is already underway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390316,"accession_number":"0001570562-22-000064","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2022-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolus Q4 revenue $34.7M (+68% YoY); 2021 revenue $99.7M (+76%); 2022 guidance $143-150M reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 net revenue $34.7M, up 68% from Q4 2020; full-year revenue $99.7M, up 76% over 2020.","Cash and cash equivalents $146.3M at Dec 31, 2021, including $68.7M from first tranche of $125M term loan.","Reaffirmed FY2022 revenue guidance of $143-150M (43-50% YoY growth); expects adjusted gross margin 58-61%.","Added 400 new accounts in Q4 and 1,400 in 2021; total accounts >7,000 with reorder rate >70%.","Phase II extra-strength Jeuveau study on track for first patient Q1 2022; Nuceiva EU launch planned Q3 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390315,"accession_number":"0001570562-22-000015","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2022-01-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolus reports Q4 preliminary revenue $34.7M (+68% YoY), guides 2022 revenue $143-150M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 preliminary net revenue $34.7M, up 68% YoY; full-year 2021 revenue $99.7M, up 76% YoY.","Cash position $146.3M at Dec 31, 2021; expects sufficient funding through cash flow breakeven.","2022 net revenue guidance $143-150M (43-50% growth); adjusted gross margin 58-61% full year, improving to 68-71% in Q4.","Plans to initiate Phase 2 'extra strength' Jeuveau trial in Q1 2022; European Nuceiva launch in Q3 2022.","Added 1,400+ new accounts in 2021; consumer loyalty program reached 270,000+."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":99673000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390314,"accession_number":"0001570562-22-000004","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2022-01-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Evolus appoints Brady Stewart to Board of Directors effective Jan 5, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Brady Stewart as Class II director, term expiring at 2023 annual meeting.","Stewart receives RSUs valued at ~$230,000 vesting over 2 years, plus $42,000 annual retainer.","Stewart is Chief Commercial Officer of Forma Brands, with 20+ years in digital/beauty DTC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408312,"accession_number":"0001570562-21-000177","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2021-12-14T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Evolus enters $125M credit facility with Pharmakon Advisors; initial $75M draw","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$75M drawn at close; up to $50M additional tranche available until Dec 31, 2022.","Facility matures in 6 years, interest-only for first 39 months; rate = 3-month LIBOR (1% floor) + 8.5%.","Proceeds for general corporate, working capital, and potential strategic transactions.","Company expects initial tranche to fund operations beyond cash flow breakeven, removing near-term equity dilution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408311,"accession_number":"0001570562-21-000171","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2021-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolus Q3 revenue $26.7M (+58% YoY); record sales; initiates extra-strength Jeuveau Phase II","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["U.S. net revenue of $26.7M, up 58% YoY; total net revenue up 51% to $26.7M.","GAAP operating loss $19.1M vs. $8.8M YoY; non-GAAP operating loss $14.3M vs. $6.5M.","Cash $107.8M at Sept 30, down from $131.7M due to $15M milestone payment.","Initiated Phase II for extra-strength Jeuveau; first patient expected Q1 2022, completion 1H 2023.","Accounts purchasing Jeuveau increased by 500 to >6,500; loyalty program doubled to 240,000 registrants."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":65016000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":427274,"accession_number":"0001570562-21-000147","cik":1570562,"company_name":"Evolus, Inc.","ticker":"EOLS","form_type":"8-K","filed_at":"2021-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolus Q2 net revenue up 235% YoY to $26.1M; raises gross margin target","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Jeuveau net revenue of $26.1M, up 235% from $7.8M in Q2 2020.","Cash and equivalents $131.7M at June 30, 2021, up from $22.2M at March 31.","GAAP loss from operations improved 19% to $15.3M; non-GAAP loss down 25% to $9.3M.","Adjusted gross margin target raised to 54%-57% for full year 2021.","European launch on track for early 2022 (estimated $470M market)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":38339000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":436616991.42718446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}